Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

Abstract

Liver cancer has high rates of morbidity and mortality, and its treatment is a global health challenge. Hepatocellular carcinoma (HCC) accounts for 90% of all primary liver cancer cases. B-lymphoma Mo-MLV insertion region 1 (BMI1) has been identified as a proto-oncogene, which contributes to the initiation and progression of many malignant tumors. BMI1 expression is upregulated in HCC, and it influences the occurrence and development of HCC by various mechanisms, such as the INK4a/ARF locus, NF-κB signaling pathway, and PTEN/PI3K/AKT signaling pathway. In addition, the expression of BMI1 is related to prognosis and recurrence of HCC. Hence, there is clear evidence that BMI1 is a novel and valid therapeutic target for HCC. Accordingly, the development of therapeutic strategies targeting BMI1 has been a focus of recent research, providing new directions for HCC treatment. This review summarizes the role of BMI1 in the occurrence and treatment of HCC, which will provide a basis for using BMI1 as a potential target for the development of therapeutic strategies for HCC.

Introduction

Liver cancer poses a global health challenge, with 905 677 new cases detected in 2020 and an estimated incidence of >1 million cases by 2025. ¹ Liver cancer is the sixth most common cancer worldwide and the fourth leading cause of cancer deaths globally. Hepatocellular carcinoma (HCC) accounts for more than 90% of all primary liver cancer cases and is the most common type of liver cancer. Current therapeutic methods for liver cancer mainly include surgical resection, liver transplantation, local ablation, external radiation, trans-arterial therapies, chemotherapy, targeted therapy, and immunotherapy. ² However, the efficacies of these strategies remain insufficient, and the mortality rate of liver cancer is still high. Therefore, to improve survival and the quality of life, new and effective treatment methods for HCC are required.

Similar to the processes involved in other cancers, the occurrence and invasion of HCC involve complicated processes, involving multiple factors and processes. A series of physiological processes involving the polycomb group (PcG) gene family, including cellular differentiation, stem cell self-renewal, and correct gene silencing, are critical for normal tissue functioning. B-lymphoma Mo-MLV insertion region 1 (BMI1) encodes a key PcG protein that ubiquitylates histone H2A by forming a stable heterodimer with RING1B. ³ BMI1 has been identified as a proto-oncogene. It encodes a protein with 324 amino acids, which is principally localized in the nucleus and contributes to the generation of mouse pre-B cell lymphomas. ⁴ BMI1 has been found in various normal cells and is highly conserved evolutionarily; moreover, it contains a type of zinc finger motif. ⁵ Accumulating evidence indicates that BMI1 is expressed at significantly high levels and is closely related to the occurrence, development, and outcomes of various human malignancies.^6–8 In endometrial adenocarcinoma, the overexpression of BMI1 is a poor prognostic factor correlated with the invasion of the myometrium and lymph nodes. ⁹ In addition, in gastric cancer, the BMI1 gene regulates tumor growth, metastasis, and chemoresistance by downregulating Raf kinase inhibitor protein (RKIP) expression. ¹⁰ Therefore, a clear understanding of the role of BMI1 in HCC is essential for the development of new therapeutic strategies. This review describes the roles of BMI1 in the occurrence, progression, and prognosis of HCC as well as the implications of recent research for treatment strategies for HCC.

BMI1 Expression Is Upregulated in HCC

Neo et al identified 218 differentially expressed genes between HCC and normal liver tissues; these genes included BMI1. ¹¹ BMI1 expression is markedly higher in HCC tissues than in normal and adjacent non-cancerous liver tissues,^12–14 consistent with the results for other cancers.^8,15,16 However, changes in the expression of BMI1 in HCC at different stages are still controversial. Sasaki et al established that the percentage of BMI1-positive cells is higher in poorly differentiated HCC (91.22 ± 5.64%) than in moderately differentiated HCC (56.94 ± 28.55%) and well-differentiated HCC (8.48 ± 11.97%). ¹⁷ In contrast, Effendi et al concluded that BMI1 expression level is the highest in well-differentiated HCC (including early HCC samples), followed by the expression in moderately differentiated and poorly differentiated HCC. ¹⁸ These conflicting results could be because of differences in analysis methods, evaluation criteria, and population differences. Both were semi-quantitative analyses; however, Sasaki et al evaluated the proportion of BMI1-positive cells in 27 HCC tissue samples (among >100 cells) under a microscope, ¹⁷ while Effendi et al evaluated tissues resected from patients with HCC by immunohistochemical staining based on a 3-point scale (0 for no staining, 1 + for focal and weak distribution, and 2 + for diffuse and clear distribution). ¹⁸ To further explore the relationship between the expression of BMI1 and the degree of HCC differentiation, Effendi et al determined BMI1 mRNA expression levels in HCC samples with different levels of differentiation and obtained similar results. Both studies proved that BMI1 is highly expressed in the nuclei in HCC. Nevertheless, correlations between high BMI1 expression levels and clinical characteristics of patients with HCC should be investigated further. Based on data for 62 patients with HCC, Li et al determined that high BMI1 expression is not statistically correlated with age, gender, satellite foci, tumor location and number, and the level of alpha-fetoprotein (AFP) but was highly correlated with neoplasm size, distant metastasis, vascular infiltration, and AJCC TNM stage. ¹⁹ Sasaki et al also detected correlations between high BMI1 expression levels and venous invasion and cancer cell proliferation, thus revealing that BMI1 accelerates disease progression and is a poor prognostic factor in HCC. ¹⁷ Surprisingly, Wang et al obtained contradictory results. They found that the expression of BMI1 was not related to the basic clinical characteristics of patients with HCC or to metastasis and postoperative recurrence, although they reported that high BMI1 levels promoted the development and progression of HCC. ²⁰ These inconsistent findings may be related to the differences in disease stage and indicate that more comprehensive and objective analyses are urgently required.

Mechanism by Which BMI1 Contributes to the Initiation of HCC

Excessive proliferation of cells plays a pivotal role in the early formation of cancers. ²¹ Several studies have demonstrated that BMI1 not only participates in the self-renewal of normal hematopoietic stem cells but also contributes greatly to the continuous proliferation of acute myelocytic leukemia stem cells without senescence and apoptosis.^22,23 It has been reported that BMI1 is required for hepatic stem cell expansion. ²⁴ Interestingly, BMI1 promotes the proliferation, colony formation, and cell cycle progression of hepatic progenitor cells in vitro, and high BMI1 expression in hepatic progenitor cells results in the occurrence of poorly differentiated HCC in nude mice. ²⁵

The initiation of HCC by BMI1 is mediated by many mechanisms (Figure 1). Chiba et al revealed that BMI1 determines the self-renewal capability of side population cells purified from HCC tissues and demonstrated the high proliferative potential and anti-apoptotic properties of these cells, ²⁶ which directly contribute to its tumorigenic potential. ²⁷ Although BMI1 can promote the self-renewal of hepatic stem cells, it has no influence on the overall cell cycle, and there is no evidence that BMI1 promotes the growth or self-renewal of differentiated cells. ²⁸ However, Ma et al reported that the downregulation of BMI1 expression could induce CD133⁺ Huh7 cell cycle arrest in the G0/G1 and S phases by blocking the NF-κB signaling pathway, thereby promoting cell apoptosis. ²⁹ It has previously been reported that BMI1 regulates the cell cycle, apoptosis, and senescence by repressing INK4a/ARF, encoding p16^ink4a, which inhibits the activity of cyclin-dependent kinase (CDK), as well as p19^ARF, a well-known tumor suppressor (Figure 2).^30–32 Direct binding of p16^INK4a to CDK4 and CDK6 maintains Rb in a hypophosphorylated state. Hypophosphorylated Rb represses E2F-dependent transcription, causing cell cycle arrest and senescence. ³³ p19^ARF suppresses MDM2, which mediates the ubiquitin-dependent degradation of p53, and subsequently activates p53 target genes involved in cell cycle arrest and apoptosis.^34,35 The increase in cell self-renewal ability induced by BMI1 in neural stem cells and glioma cells is not completely INK4a/ARF-dependent.^36,37 In a study by Chiba et al the expression levels of INK4a and ARF were increased in PLC/PRF/5 cells upon BMI1 knockdown, with no remarkable changes in Huh7 cells compared with levels in the control group. ²⁷ Intriguingly, BMI1 increased the expression of p16^INK4a and inhibited the expression of p19^ARF in mouse hepatocytes. ³⁸ Hence, Chiba et al further explored the role of the INK4a/ARF tumor suppressor gene locus in hepatic stem cell expansion and hepatocarcinogenesis. They ascertained that transfection with BMI1 alone could enhance the renewal ability of Dlk⁺ cells, without INK4a/ARF expression, demonstrating that the INK4a/ARF locus does not directly contribute to early hepatoma formation. ³⁹ Additionally, they identified five candidate genes downstream of BMI1 in hepatic stem/progenitor cells, representing a major step forward. Among the five candidate genes, Prom1 (CD133) and EpCAM are highly expressed in hepatic stem cells, whereas carbamoyl phosphate synthase I (Cps1), Mat1a, and Gjb2 show low expression in hepatocyte-differentiated cells. ³⁹ Knockout of the Mat1a gene in mice enhanced the sensitivity of hepatocytes to oxidative stress and accelerated the formation of HCC, providing powerful evidence that Mat1a is a hepatoma marker. ⁴⁰ Furthermore, Cps1 may be a key component in the progression of hepatocytes to malignant HCC cells by metabolic reprograming. ⁴¹ Nevertheless, further research is necessary to determine the relationships between these five candidate downstream targets and carcinogenesis. Chiba et al ultimately determined that BMI1 promotes hepatic stem cell expansion and tumorigenicity in both INK4a/ARF-dependent and INK4a/ARF-independent manners in mice. ³⁹ This conclusion is supported by the results of Fu et al who found that BMI1 knockdown induces G1-phase arrest and activates the p14^ARF and p16^INK4a signaling pathways in HepG2 cells, ⁴² as well as the results of Xu et al who established that the silencing of BMI1 expression does not lead to the upregulation of p14^ARF and p16^INK4a in Huh7 and Hep3B cells. ³⁸

Figure 1.

Mechanism underlying the initiation of hepatocellular carcinoma (HCC) by BMI1. Previous studies have shown that BMI1 promotes the occurrence of HCC by blocking the INK4a/ARF locus, NF-κB signaling pathway, and TGFβ2/SMAD signaling axis and by stimulating the Wnt/β-catenin signaling axis. Besides, BMI1 and Ras/MAPK signaling work together to activate the initiation of HCC. Black and red arrows represent promotion, T-shaped symbols represent inhibition, and H-shaped symbols represent interactive effects.

Figure 2.

Mechanism by which INK4a/ARF mediates the effects of BMI1. The BMI1 gene downregulates the expression of p16^INK4a and p19^ARF. Direct binding of p16^INK4a to CDK4 and CDK6 blocks the binding of CDK4/6 to cyclin D, resulting in the dephosphorylated state of Rb. Dephosphorylated Rb does not dissociate the repressive complexes of E2F, whose protein products dictate regular and correct DNA transcription, and thus prevents the release of E2F, causing cell cycle arrest and senescence. p19^ARF suppresses MDM2, which mediates the ubiquitination and degradation of p53, and can initiate related processes to promote abnormal cell cycle arrest and apoptosis during uncontrolled proliferation or irreparable damage.

Furthermore, some additional INK4a/ARF-independent mechanisms have been reported. It has been proposed that BMI1 functions synergistically with activated Ras/MAPK signaling and inhibits the TGFβ2/SMAD signaling axis to induce the occurrence of HCC.^38,43 BMI1 stimulates the Wnt/β-catenin signaling axis to increase the expression levels of cyclin D1, c-myc, and E-cadherin, thereby activating HCC cell proliferation. ⁴⁴ These findings unequivocally demonstrate that BMI1 mediates the occurrence of HCC by complex and diverse mechanisms. In the future, these mechanisms should be explored further to provide more ideas for the treatment of HCC.

Relationship Between BMI1 and the Progression of HCC

Metastasis and invasion are crucial hallmarks of cancer progression. BMI1 is important for the invasion and metastasis of various cancers,^45,46 including HCC. ¹⁹ Cancer invasion and metastasis are complex and multi-factorial processes that involve tumor angiogenesis, extracellular matrix degradation, and the epithelial-to-mesenchymal transition (EMT). ⁴⁷ Li et al have revealed that BMI1 can inhibit the PTEN/PI3K/AKT signaling pathway in HCC, ultimately stimulating metastasis by increasing the expression and activity of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-9, and MMP-2. ¹⁹ PTEN that encodes the protein phosphatase phosphatase and tensin homolog is mutated or lost in various human cancers, including HCC. ⁴⁸ PTEN acts as a negative regulator of the PI3K/AKT signaling pathway in cells. ⁴⁹ Tumor growth and migration are inseparable from the nutritional support provided by the blood; VEGF has important roles in tumor angiogenesis and metastasis. Matrix metalloproteinases are the common extracellular matrix-degrading enzymes. The expression levels of MMP-2 and MMP-9 are markedly upregulated in later TNM stages of HCC, and there is a significant correlation between MMP-9 (but not MMP-2) and PTEN in HCC. ⁵⁰ MMP-9 is upregulated via the PI3K/AKT/NF-κB signaling pathway, which promotes HCC metastasis and invasion. ⁵¹

BMI1 overexpression accelerates the progression of HCC by inducing EMT. Vimentin is beneficial for EMT, whereas E-cadherin inhibits this process. ⁵² Zhang et al demonstrated that high BMI1 expression decreased E-cadherin levels and increased vimentin levels in CD133⁺ HepG2 cells, which are regarded as representative HCC stem cells. ⁵³ These results are consistent with those of studies on breast and colon cancer.^6,45 The NF-κB signaling pathway has been identified as a key regulator of EMT in a variety of cancers.^54,55 Intriguingly, Ma et al obtained similar results and found that BMI1 knockdown inhibits the metastasis of CD133⁺ Huh7 cells by inhibiting the NF-κB pathway. ²⁹ In addition, Twist2, a primary helix-loop-helix transcription factor, regulates the progression of EMT in many cancers.^56–58 A previous study has indicated that Twist2-expressing HepG2 cells exhibit an increase in the expression of the stem cell marker BMI1. ⁵⁹ Therefore, further research is necessary to identify the links between the BMI1 proto-oncogene and EMT in HCC.

Recently, new mechanisms by which BMI1 affects the invasion and metastasis of cancers have been reported. BMI1 negatively regulates RKIP expression via miR-27a and miR-155, thus promoting tumor metastasis and chemoresistance. ¹⁰ These findings provide new directions for research on the mechanisms mediating the effect of BMI1 on HCC progression.

High BMI1 Expression Effectively Indicates Prognosis in HCC

Consistent with the association between BMI1 and prognosis in other cancers,^9,60 high BMI1 levels are related to relatively poor outcomes in HCC, indicating that BMI1 is a reliable prognostic factor. ¹⁹ It is striking that BMI1 knockdown can enhance the sensitivity of HCC cells to sorafenib and 5-fluorouracil, which are promising and frequently used drugs for HCC.^61,62 Wang et al found that the 5-year survival rate of patients with HCC from China with low BMI1 expression is 46%, compared with only 15% for the patients with high BMI1 expression after routine surgery without prior radiotherapy or chemotherapy. ²⁰ There was an approximately three-fold gap in the survival rate between the two groups, which was quite substantial. Of note, there was no significant difference in the survival rate of patients with high BMI1 levels and those with low BMI1 levels in 2 years, as determined by a Kaplan–Meier curve analysis. ²⁰ These findings suggest that BMI1 is an important biomarker for predicting the long-term survival of patients with HCC. However, Yonemitsu et al concluded that the expression level of BMI1 had no apparent effect on the survival of patients with HCC after resection in Japan, although high BMI1 protein levels were correlated with the recurrence rate after hepatectomy. ⁶³ These inconsistent results imply that the prognostic value of BMI1 expression in HCC patients differs among regions/territories. A meta-analysis suggested that high BMI1 expression predicts an adverse overall survival rate for cancer patients in Asian populations and as a favorable predictor in Caucasian populations. ⁶⁴ Another meta-analysis also suggested that high BMI1 expression is associated with lower overall survival rates in patients with colorectal cancer in Asia and is associated with higher overall survival rates in European populations. ⁶⁵

Overview of HCC Therapy Targeting BMI1

The link between BMI1 and the initiation and progression of HCC is well-established. Therefore, several researchers have investigated the potential of BMI1 as a target for the treatment of HCC (Table 1).

Table 1.

The Overview of Potential Therapeutic Strategies Targeting BMI1 in HCC Treatment.

Therapeutic strategies targeting BMI1	Category	Reference
Compounds inhibiting BMI1 expression	PTC-209	66
	PTC-028	67
	PTC-596	68
	QW24	69
	RU-A1	70
Increasing the expression of MicroRNAs downregulating BMI1 level	1,6,7-trihydroxyxanthone(THA) upregulating miR-218	76
	Luteolin and sevoflurane upregulating miR-203	81 to 83
	Short-chain fatty acid sodium butyrate (NaB) upregulating miR-200c	87
Natural extracts suppressing BMI1 expression	Jiedu Xiaozheng Yin (JXY)	88
	Wallichoside	89
Combinations of chemotherapeutical agent and BMI1- siRNA	Nanoplatin and siRNA co-loaded CaP nanoparticles (NPSC) delivering cisplatin and BMI1- siRNA	92
	Nanocapsules delivering BMI1- siRNA and cisplatin cationic	93
Genome editing	Clustered regularly interspaced short palindromic repeats and CRISPR associated protein-9(CRISPR-Cas9)	97 to 99

Previous studies have identified BMI1 inhibitors, including PTC-209, PTC-028, PTC-596, and QW24. PTC-209 was the first reported BMI1 inhibitor. It is a low-molecular-weight compound identified by high-throughput screening using the GEMS (Gene Expression Modulation by Small Molecules) platform. ⁶⁶ Kreso et al demonstrated that PTC-209 decreases BMI1 expression at the protein level and causes the loss of tumor-initiating cells in primary colorectal cancer as well as irreversible intra-tumor injury. ⁶⁶ PTC-028 decreases BMI1 function via hyper-phosphorylation and induces apoptosis in epithelial ovarian cancer cells. ⁶⁷ Likewise, PTC-596, identified as a novel BMI1 inhibitor, can promote the apoptosis of acute myeloid leukemia progenitor cells. ⁶⁸ Wang et al demonstrated that QW24, a small-molecule inhibitor against BMI1, could reduce the stability of the BMI1 protein and downregulate BMI1 expression via the autophagy-lysosome pathway, without affecting BMI1 mRNA levels in colorectal cancer cells. ⁶⁹ Bartucci et al identified BMI1 inhibitors, named RU-A1 compounds, by medicinal chemistry and chemical engineering, which can inhibit HCC cell growth, chemosensitivity, and tumor-initiating capacity, with more effective tumor-suppressive effects than those of PTC-209. ⁷⁰ These BMI1 inhibitors may be effective therapeutic agents for cancer in the future. However, BMI1 inhibitors have not been used in HCC clinical treatment to date and the efficacy of these inhibitors against HCC is not clear.

MicroRNAs are a group of endogenous noncoding single-stranded RNAs that negatively regulate the expression of target genes. ⁷¹ MiR-218 has suppressive effects in many cancers.^72–74 Furthermore, accumulating evidence indicates that miR-218 negatively regulates BMI1 expression in HCC^14,75,76 and is an independent prognostic factor for HCC. ⁷⁷ Hence, reducing the expression of BMI1 by increasing the expression of miR-218 may be an effective treatment strategy for HCC. Fu et al found that 1,6,7-trihydroxyxanthone (THA), an active ingredient derived from Goodyera oblongifolia, could increase miR-218 expression and decrease BMI1 expression, thereby strongly inhibiting cancer cell growth and inducing abnormal cell apoptosis in HCC. ⁷⁶ Similarly, some studies have demonstrated that miR-203 has suppressive effects in numerous tumors. ⁷⁸ A study has shown that miR-203 levels are lower in HCC tissue samples than in normal tissues and the overexpression of miR-203 could suppress the proliferation and invasion of HCC cells. ⁷⁹ Interestingly, miR-203 can enhance the radiosensitivity of HCC cells by directly targeting BMI1. ⁸⁰ Therefore, miR-203 may be a valid therapeutic target for HCC, as it inhibits BMI1 expression. Recently, some progress has been made in the elucidation of miR-203-based regulation. For example, luteolin, a natural flavonoid, possesses anti-breast cancer properties, as it upregulates miR-203 expression. ⁸¹ Strikingly, sevoflurane, an inhalational anesthetic, suppresses cell proliferation in breast cancer and migration in colorectal cancer by upregulating miR-203 expression.^82,83 In addition, BMI1 is a well-known target gene of the miR-200 family, which plays an essential role in cancer progression and metastasis.^84,85 A recent study has proven that miR-200c suppresses the initiation of HCC, at least in part by inhibiting BMI1 expression. ⁸⁶ Interestingly, the short-chain fatty acid sodium butyrate (NaB) produced by bacterial fermentation of dietary fiber in the colon limits colorectal cancer liver metastasis by downregulating BMI1 expression by enhanced miR-200c expression. ⁸⁷ These results provide potential therapeutic agents for HCC.

Many studies have inspired new ideas for the development of HCC treatments targeting BMI1. Jiedu Xiaozheng Yin (JXY), a Chinese herbal decoction, inhibits HCC cell growth by suppressing BMI1 expression. ⁸⁸ Kaneta et al identified that wallichoside, a methanol-soluble extract from Beaumontia murtonii and Eugenia operculate, suppressed BMI1 promoter activity and inhibited the growth of Huh7 human hepatocellular carcinoma cells. ⁸⁹ Small interfering RNAs (siRNAs) can silence specific cancer genes; thus, siRNA therapeutics are very promising and are a focus of cancer research. ⁹⁰ Cisplatin (cis-dichlorodiamminoplatinum [II]; CDDP) is an anticancer agent used widely in HCC treatment. ⁹¹ Li et al designed Nanoplatin and siRNA co-loaded CaP nanoparticles to deliver the chemotherapeutical agent CDDP and BMI1 siRNA to effectively and safely treat HCC; the upregulation of BMI1 expression under CDDP-exposure contributed to drug resistance in HCC cell lines. ⁹² Yang et al found that BMI1 siRNA and cisplatin cationic nanocapsules delivered to HCC-bearing mice had higher anti-tumor activity than that of mice treated with nanocapsules alone. ⁹³

Genome editing is an emerging area of research because of its ability to precisely alter genomes of target cells and regulate functional genes using targeted nucleases. Clustered regularly interspaced short palindromic repeats and CRISPR associated protein-9 (CRISPR-Cas9) acts as “molecular scissors” and is quicker, more precise, and more effective than alternative genome-editing strategies. ⁹⁴ CRISPR-Cas9 has also shown great potential in the treatment of cancer, including HCC.^95,96 Wang et al reported that the knockout of CXC chemokine receptor 4 (CXCR4), associated with a poor prognosis in HCC, by CRISPR/Cas9 not only suppresses proliferation and invasion but also increases sensitivity to the anticancer drug cisplatin in HCC. ⁹⁷ Another study has shown that the CRISPR/Cas9-mediated knockout of nuclear receptor binding SET domain-containing protein 1 inhibits the ability of HCC cells to proliferate and migrate. ⁹⁸ In addition, Zhao et al applied the CRISPR/Cas9 technique to knock out BMI1 in epithelial ovarian cancer cells and found that the knockout of BMI1 could promote cell apoptosis and reduce cell growth and metastasis. ⁹⁹ These results suggest that CRISPR/Cas9-mediated BMI1 knockout is feasible for the treatment of HCC, and relevant research is urgently needed.

Conclusion

BMI1 is a key gene in tumorigenesis and contributes to the development of many cancers, making it a well-established therapeutic target. In this review, we introduced the characteristics of BMI1 expression in the occurrence and development of HCC and briefly summarized the mechanisms by which BMI1 influences disease progression. Accumulating evidence shows that in some cancers, suppressing the expression and activity of BMI1 by direct inhibition or by suppressing upstream factors is a highly efficient treatment strategy. In addition, considering the biological availability of BMI1 inhibitors in clinical application, innovative drug combinations and agents have also shown promising results. Although such inhibitors are not widely used in clinical practice, there is sufficient evidence that BMI1 is an effective therapeutic target for HCC. Therefore, further studies to elucidate the basic mechanism of action of BMI1 in HCC and its clinical correlations are needed.

Abbreviations

AFP

Alpha-fetoprotein

BMI1

B-lymphoma Mo-MLV insertion region 1

CDK

cyclin-dependent kinase

CDDP

cis-dichlorodiamminoplatinum (II)

Cps1

carbamoyl phosphate synthase I

CRISPR-Cas9

clustered regularly interspaced short palindromic repeats and CRISPR associated protein-9

CXCR4

CXC chemokine receptor 4

ECM

the extracellular matrix

EMT

epithelial-to-mesenchymal transition

GEMS

Gene Expression Modulation by Small Molecules

HCC

Hepatocellular carcinoma

HPCs

hepatic progenitor cells

JXY

Jiedu Xiaozheng Yin

MMP

matrix metalloproteinase

NPSC

Nanoplatin and siRNA co-loaded CaP nanoparticles

PcG

polycomb group

RKIP

Raf kinase inhibitor protein

siRNAs

small interfering RNAs

THA

1,6,7-trihydroxyxanthone

VEGF

vascular endothelial growth factor.